Announcement no. 11/2008
To the NASDAQ OMX Nordic Exchange Copenhagen Copenhagen, June
23, 2008
Share capital increase as a result of warrant exercise
Summary: Curalogic issues new shares today as a result of the exercise by a
former employee of warrants granted in 2005
Curalogic increases the share capital by a nominal value of DKK 25,666.5
corresponding to 51,333 shares with a nominal value of DKK 0.5 each as a result
of the exercise by a former employee of warrants granted in 2005.
Pursuant to Appendix 2 to the company's Articles of Association about the
warrant plan, the new shares are issued without preemptive rights to the
company's existing shareholders or others at an exercise price of DKK 1.55 per
share with a nominal value of DKK 0.5 each. The new shares will be admitted for
listing on the NASDAQ OMX following registration with the Danish Commerce and
Companies Agency, which is expected to take place on June 23, 2008.
The registered share capital will subsequently amount to a nominal value of DKK
28,240,074.5 divided into 56,480,149 shares of DKK 0.50 each.
Yours sincerely,
Curalogic A/S
For additional information, please contact:
Peter Moldt, President and CEO, Phone +45 99 99 24 01
Helle Busck Fensvig, EVP and CFO, Phone +45 99 99 24 03
About Curalogic
Curalogic is a Danish biopharmaceutical company listed on NASDAQ OMX Nordic
Exchange Copenhagen (CUR.CO) as a SmallCap+ company. Curalogic has ample cash
resources and has demonstrated its ability to conduct complex clinical studies
with a small group of development experts. Curalogic has initiated a search
process to identify development projects offering an attractive risk profile.
Curalogic expects to conclude an agreement during 2008 that will secure future
clinical development projects for the Company.
This announcement contains forward-looking statements regarding the Company's
future financial development and performance and other statements which are not
historical facts. Such statements are made on the basis of assumptions and
expectations which, to the best of the Company's knowledge and belief, are
reasonable, at this time, but may prove to be erroneous in the future.
